E-ISSN: 2619-9467

Contents    Cover    Publication Date: 20 Sep 2023
Year 2023 - Volume 33 - Issue 3

Open Access

Peer Reviewed

612 Viewed495 Downloaded

Vaginal Health in Menopausal Peruvian Women: Descriptive Research

Full Text PDF  
JCOG. 2023;33(3):151-6
DOI: 10.5336/jcog.2023-96111
Article Language: EN
Copyright Ⓒ 2020 by Türkiye Klinikleri. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Objective: To analyze vaginal health based on three dimensions: symptoms, information, and treatment in menopausal Peruvian women attended in first level health care facilities. Material and Methods: This is a descriptive, prospective, cross-sectional research, with the participation of women attended in first level health care facilities during the year 2021. A non-probability sample of 855 women was used. A vaginal health survey composed of 26 indicators was used through 3 dimensions: symptoms, information, and treatment, with a reliability coefficient of 0.79. Results: The mean age was 54.8±6.4 years, 67.8% had no knowledge of hormone therapy for menopause, while 80.9% said they did not use it. In the symptoms dimension: 22.6% experienced hot flashes frequently and 15.2% had vaginal symptoms (dryness, burning, and soreness), 54.9% considered them as a mild discomfort and described the symptoms as part of aging. In the information dimension: 60.4% stated that there is not enough information; 44.6% of women have access to information through their gynecologists, and 46.9% feel comfortable asking about treatment options. In the treatment dimension: 39.2% consider hormonal vaginal suppositories as an effective treatment; 23.5% did not use any treatment; and 73.8% would consider using hormone therapy during menopause. Conclusion: There was a high prevalence of vasomotor and vaginal symptoms affecting quality of life. The information given to patients was insufficient despite being provided by the gynecologist. There is acceptance for the use of local estrogen therapy.
  1. U.S. Census Bureau. Current population reports: Population projections of the United States 1977 to 2050. Washington: U.S. Government Printing Office 1993. [Cited: Nov 22, 2022]. Available from: [Link] 
  2. Lobo RA. Menopause and aging. In: Strauss JF, Barbieri RL, Gargiulo AR, Yen SSC, Jaffe RB, eds. Yen and Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management. 8th ed. Amsterdam: Elsevier; 2019. p.322-56. [Crossref] 
  3. Matzumura-Kasano JP, Gutiérrez-Crespo HF, Wong-Mac JI, Alamo-Palomino IJ. Instrumento para la evaluación del climaterio y la menopausia en el primer nivel de atención (Instrument for Climacteric and Menopausal Evaluation in the First Care Level). Rev. Fac. Med. Hum. 2020;20(4):560-67. [Crossref] 
  4. Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, et al; Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-9. [Crossref]  [PubMed]  [PMC] 
  5. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000;96(3):351-8. [Crossref]  [PubMed] 
  6. Nappi RE, Kokot-Kierepa M. Vaginal health: insights, views & attitudes (VIVA) - results from an international survey. Climacteric. 2012;15(1):36-44. [Crossref]  [PubMed] 
  7. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87-94. [Crossref]  [PubMed]  [PMC] 
  8. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician. 2000;61(10):3090-6. [PubMed] 
  9. Gass ML, Cochrane BB, Larson JC, Manson JE, Barnabei VM, Brzyski RG, et al. Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women's Health Initiative. Menopause. 2011;18(11):1160-71. [Crossref]  [PubMed] 
  10. Parish SJ, Nappi RE, Krychman ML, Kellogg-Spadt S, Simon JA, Goldstein JA, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health. 2013;5:437-47. [Crossref]  [PubMed]  [PMC] 
  11. Kim HK, Kang SY, Chung YJ, Kim JH, Kim MR. The recent review of the genitourinary syndrome of menopause. J Menopausal Med. 2015;21(2):65-71. [Crossref]  [PubMed]  [PMC] 
  12. Kim TH, Lee ES, Lee HH, Kim JM, Kim YS, Lee B. Vaginal Health: Insights, Views and Attitudes (VIVA). Results from a survey in South Korea. Clin Exp Obstet Gynecol. 2019;46(6):938-42. [Crossref] 
  13. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009;6(8):2133-42. [Crossref]  [PubMed] 
  14. Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13(6):509-22. [Crossref]  [PubMed] 
  15. Krychman M, Graham S, Bernick B, Mirkin S, Kingsberg SA. The Women's EMPOWER survey: women's knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. J Sex Med. 2017;14(3):425-33. [Crossref]  [PubMed] 
  16. Nappi RE, Palacios S, Particco M, Panay N. The REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey in Europe: Country-specific comparisons of postmenopausal women's perceptions, experiences and needs. Maturitas. 2016;91:81-90. [Crossref]  [PubMed] 
  17. Blümel JE, Chedraui P, Baron G, Belzares E, Bencosme A, Calle A, et al; Collaborative Group for Research of the Climacteric in Latin America (REDLINC). Sexual dysfunction in middle-aged women: a multicenter Latin American study using the Female Sexual Function Index. Menopause. 2009;16(6):1139-48. [Crossref]  [PubMed] 
  18. Nappi RE, de Melo NR, Martino M, Celis-González C, Villaseca P, Röhrich S, et al. Vaginal Health: Insights, Views & Attitudes (VIVA-LATAM): results from a survey in Latin America. Climacteric. 2018;21(4):397-403. [Crossref]  [PubMed] 
  19. Pompei LM, Wender MCO, de Melo NR, Kulak J Jr, Pardini D, Machado RB, et al. Vaginal Health: Insights, Views & Attitudes survey in Latin America (VIVA-LATAM): focus on Brazil. Climacteric. 2021;24(2):157-63. [Crossref]  [PubMed] 
  20. Palma F, Volpe A, Villa P, Cagnacci A; Writing group of AGATA study. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study. Maturitas. 2016;83:40-4. [Crossref]  [PubMed] 
  21. Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The women's EMPOWER survey: identifying women's perceptions on vulvar and vaginal atrophy and its treatment. J Sex Med. 2017;14(3):413-24. [Crossref]  [PubMed] 
  22. Nappi RE, Seracchioli R, Salvatore S, Cagnacci A, Di Paolantonio T, Busacca M; investigators of the EVES Study. Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study. Gynecol Endocrinol. 2019;35(5):453-9. [Crossref]  [PubMed] 
  23. Moral E, Delgado JL, Carmona F, Caballero B, Guillán C, González PM, et al; as the writing group of the GENISSE study. Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Climacteric. 2018;21(2):167-73. [Crossref]  [PubMed] 
  24. Cagnacci A, Xholli A, Sclauzero M, Venier M, Palma F, Gambacciani M; writing group of the ANGEL study. Vaginal atrophy across the menopausal age: results from the ANGEL study. Climacteric. 2019;22(1):85-9. [Crossref]  [PubMed] 
  25. Nappi RE, Particco M, Biglia N, Cagnacci A, Di Carlo C, Luisi S, et al. Attitudes and perceptions towards vulvar and vaginal atrophy in Italian post-menopausal women: Evidence from the European REVIVE survey. Maturitas. 2016;91:74-80. [Crossref]  [PubMed] 
  26. Jin F, Tao M, Teng Y, Shao H, Li C, Mills E. Knowledge and attitude towards menopause and hormone replacement therapy in Chinese women. Gynecol Obstet Invest. 2015;79(1):40-5. [Crossref]  [PubMed] 
  27. Nappi RE, Palacios S, Panay N, Particco M, Krychman ML. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric. 2016;19(2):188-97. Erratum in: Climacteric. 2016;19(2):i. [Crossref]  [PubMed]  [PMC] 
  28. Panay N, Palacios S, Bruyniks N, Particco M, Nappi RE; EVES Study investigators. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas. 2019;124:55-61. [Crossref]  [PubMed] 
  29. Naumova I, Castelo-Branco C. Current treatment options for postmenopausal vaginal atrophy. Int J Womens Health. 2018;10:387-95. [Crossref]  [PubMed]  [PMC] 
  30. Utian WH, Maamari R. Attitudes and approaches to vaginal atrophy in postmenopausal women: a focus group qualitative study. Climacteric. 2014;17(1):29-36. [Crossref]  [PubMed]  [PMC] 
  31. Simon JA, Kokot-Kierepa M, Goldstein J, Nappi RE. Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey. Menopause. 2013;20(10):1043-8. [Crossref]  [PubMed] 
  32. Lui-Filho JF, Pedro AO, Baccaro LF, Costa-Paiva L. Risk factors associated with intensity of climacteric symptoms in Brazilian middle-aged women: a population-based household survey. Menopause. 2018;25(4):415-22. [Crossref]  [PubMed]